Tiziana Life Sciences Appoints New Chief Executive Officer
Tiziana Life Sciences (Nasdaq: TLSA) has appointed Ivor Elrifi as its new Chief Executive Officer, effective immediately. Elrifi, formerly the global head of the Patent Group at Cooley, brings extensive experience in intellectual property strategies and business development in the biotech and pharma sectors. Tiziana, focused on developing immunomodulation therapies, aims to accelerate its clinical trials for intranasal foralumab in treating non-active Secondary Progressive Multiple Sclerosis, Alzheimer's Disease, and ALS under Elrifi's leadership.
Gabriele Cerrone, Founder and Executive Chairman, expressed confidence in Elrifi's ability to create substantial value for the company. Elrifi's background includes guiding clients in strategic transactions and M&A involving major pharmaceutical companies. He succeeds Cerrone, who will continue as Executive Chairman, focusing on advancing Tiziana's scientific agenda.
Tiziana Life Sciences (Nasdaq: TLSA) ha nominato Ivor Elrifi come suo nuovo Amministratore Delegato, con effetto immediato. Elrifi, ex capo globale del Patent Group di Cooley, porta con sé una vasta esperienza in strategie di proprietà intellettuale e sviluppo commerciale nei settori biotech e pharma. Tiziana, focalizzata sullo sviluppo di terapie di immunomodulazione, mira ad accelerare i suoi studi clinici per foralumab intranasale nel trattamento della Sclerosi Multipla Secondaria Progressiva non attiva, della malattia di Alzheimer e della SLA sotto la guida di Elrifi.
Gabriele Cerrone, Fondatore e Presidente Esecutivo, ha espresso fiducia nella capacità di Elrifi di creare un valore sostanziale per l'azienda. Il background di Elrifi include la guida di clienti in transazioni strategiche e M&A coinvolgenti grandi aziende farmaceutiche. Elrifi succede a Cerrone, che continuerà come Presidente Esecutivo, concentrandosi sull'avanzamento dell'agenda scientifica di Tiziana.
Tiziana Life Sciences (Nasdaq: TLSA) ha nombrado a Ivor Elrifi como su nuevo Director Ejecutivo, con efecto inmediato. Elrifi, anteriormente jefe global del Patent Group en Cooley, aporta una amplia experiencia en estrategias de propiedad intelectual y desarrollo empresarial en los sectores biotech y pharma. Tiziana, centrada en el desarrollo de terapias de inmunomodulación, tiene como objetivo acelerar sus ensayos clínicos para foralumab intranasal en el tratamiento de la Esclerosis Múltiple Secundaria Progresiva no activa, la enfermedad de Alzheimer y la ELA bajo el liderazgo de Elrifi.
Gabriele Cerrone, Fundador y Presidente Ejecutivo, expresó confianza en la capacidad de Elrifi para crear un valor sustancial para la empresa. El historial de Elrifi incluye guiar a clientes en transacciones estratégicas y fusiones y adquisiciones que involucran a grandes compañías farmacéuticas. Elrifi sucede a Cerrone, quien continuará como Presidente Ejecutivo, centrándose en avanzar la agenda científica de Tiziana.
티지아나 라이프 사이언스(Tiziana Life Sciences, Nasdaq: TLSA)는 아이보르 엘리피를 새로운 CEO로 임명했다고 즉시 발표했습니다. 엘리피는 코울리의 글로벌 특허 그룹 책임자를 역임하며, 생물공학 및 제약 분야에서 지적 재산 전략과 비즈니스 개발에 대한 폭넓은 경험을 가지고 있습니다. 티지아나는 면역 조절 요법 개발에 주력하고 있으며, 엘리피의 지도 아래 비활성 이차 진행성 다발성 경화증, 알츠하이머병 및 ALS 치료를 위한 비강 내 포랄루맙의 임상 시험을 가속화할 계획입니다.
가브리엘레 체르론, 창립자 겸 회장, 엘리피가 회사에 상당한 가치를 창출할 수 있을 것이라는 자신감을 표현했습니다. 엘리피는 주요 제약 회사를 포함한 전략적 거래 및 M&A에서 클라이언트를 안내한 경력을 가지고 있습니다. 엘리피는 체르론의 뒤를 이어 회장직을 계속 맡고 있으며, 티지아나의 과학적 의제를 발전시키는 데 집중할 것입니다.
Tiziana Life Sciences (Nasdaq: TLSA) a nommé Ivor Elrifi comme nouveau PDG, avec effet immédiat. Elrifi, anciennement responsable mondial du groupe de brevets chez Cooley, apporte une vaste expérience en stratégies de propriété intellectuelle et en développement commercial dans les secteurs de la biotechnologie et de la pharmacie. Tiziana, axée sur le développement de thérapies d'immunomodulation, vise à accélérer ses essais cliniques pour le foralumab intranasal dans le traitement de la sclérose en plaques secondaire progressive non active, de la maladie d'Alzheimer et de la SLA sous la direction d'Elrifi.
Gabriele Cerrone, fondateur et président exécutif, a exprimé sa confiance dans la capacité d'Elrifi à créer une valeur substantielle pour l'entreprise. Le parcours d'Elrifi inclut la direction de clients dans des transactions stratégiques et des fusions-acquisitions avec d'importantes entreprises pharmaceutiques. Il succède à Cerrone, qui continuera en tant que président exécutif, en se concentrant sur l'avancement de l'agenda scientifique de Tiziana.
Tiziana Life Sciences (Nasdaq: TLSA) hat Ivor Elrifi zum neuen CEO ernannt, mit sofortiger Wirkung. Elrifi, ehemaliger globaler Leiter der Patentgruppe bei Cooley, bringt umfangreiche Erfahrung in den Bereichen geistiges Eigentum und Geschäftsentwicklung in den Biotech- und Pharmasektoren mit. Tiziana, das sich auf die Entwicklung von Immunmodulationstherapien konzentriert, hat zum Ziel, unter Elrifi die klinischen Studien für intranasales Foralumab zur Behandlung der nicht aktiven sekundären progressiven Multipler Sklerose, der Alzheimer-Krankheit und der ALS zu beschleunigen.
Gabriele Cerrone, Gründer und Executive Chairman, äußerte Vertrauen in Elrifis Fähigkeit, erheblichen Wert für das Unternehmen zu schaffen. Elrifis Hintergrund umfasst die Betreuung von Kunden in strategischen Transaktionen und M&A, die bedeutende Pharmaunternehmen betreffen. Er folgt auf Cerrone, der weiterhin als Executive Chairman fungieren wird und sich auf die Förderung der wissenschaftlichen Agenda von Tiziana konzentrieren wird.
- Appointment of experienced CEO with strong background in biotech and pharma sectors
- New CEO's expertise in intellectual property strategies and business development
- Potential acceleration of clinical trials for intranasal foralumab
- Focus on addressing significant unmet medical needs in multiple sclerosis, Alzheimer's, and ALS
- None.
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the appointment of Ivor Elrifi as its Chief Executive Officer (CEO), effective immediately.
"We are delighted to welcome Ivor Elrifi as the new CEO of Tiziana Life Sciences," said Gabriele Cerrone, Founder and Executive Chairman of the Board. " Ivor has an invaluable track record in creating substantial value for biotech and pharma companies with his strategic vision in building intellectual property portfolios and transforming the IP into transformative business development deals and M&A transactions. Tiziana looks forward to creating further value with Ivor as we proceed with our human clinical trials."
Tiziana Life Sciences is currently focused on advancing intranasal foralumab through clinical trials for non-active Secondary Progressive Multiple Sclerosis (na-SPMS), Alzheimer’s Disease and ALS. Under Ivor’s leadership, the company aims to accelerate these programs and capitalize on opportunities to address significant unmet medical needs.
Ivor was formerly the global head of the Patent Group at Cooley since 2014 and before that the global head of Patents at Mintz Levin from 1999 – 2014. He has counseled companies in various key industries, including pharmaceutical, biotechnology, life sciences and medical device companies, research institutions, universities, hospitals and governments throughout the world, particularly in the US and Europe. Ivor has guided clients in developing and implementing intellectual property strategies and in the prosecution, licensing and enforcement of patents. He has extensive experience in advising clients on strategic transactional work and regularly counsels’ clients with respect to investments, business development and mergers and acquisitions, including acquisition transactions involving Novartis, Eli Lilly, Biogen and Astellas.
He has received various awards throughout his career, including being named an "LMG Life Sciences: Life Science Star," and ranked nationally in Chambers USA since 2007. Elrifi earned his B.S. and Ph.D. in Biology from Queen's University and his J.D. from Osgoode Hall Law School.
"I am honored to lead Tiziana Life Sciences at this pivotal time in its growth trajectory," said Ivor Elrifi. "The company's commitment to developing transformative therapies holds great promise, and I look forward to working with the talented team to advance our clinical programs and deliver value to patients and shareholders."
Mr. Elrifi succeeds Gabriele Cerrone, who was acting CEO and will remain in his role as Executive Chairman of the board and will continue to play a key role in advancing Tiziana's scientific agenda.
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program with either an improvement or stability of disease seen within 6 months in all patients. The FDA has recently allowed an additional 20 patients to be enrolled in this EA program. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).
Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November of 2023. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
Investors:
Irina Koffler
LifeSci Advisors, LLC
646.970.4681
email: ikoffler@lifesciadvisors.com
[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0208ae67-37fe-44e0-8301-45b4cbf6edda
FAQ
Who is the new CEO of Tiziana Life Sciences (TLSA)?
What is Tiziana Life Sciences' (TLSA) main development candidate?
What medical conditions is Tiziana Life Sciences (TLSA) targeting with its clinical trials?
What was Ivor Elrifi's previous position before joining Tiziana Life Sciences (TLSA)?
